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Abstract
Purpose
Despite recommendations for 99mTc-tetrofosmin dual tracer imaging for hyperparathyroid-
ism in current guidelines, no report was published on dual-isotope 99mTc-tetrofosmin and
123I sodium iodide single-photon-emission-computed-tomography (SPECT). We evaluated
diagnostic accuracy and the impact of preoperative SPECT on the surgical procedures and
disease outcomes.
Methods
Analysis of 70 consecutive patients with primary hyperparathyroidism and 20 consecutive
patients with tertiary hyperparathyroidism. Imaging findings were correlated with surgical re-
sults. Concomitant thyroid disease, pre- and postoperative laboratory measurements, histo-
pathological results, type and duration of surgery were assessed.
Results
In primary hyperparathyroidism, SPECT had a sensitivity of 80% and a positive predictive
value of 93% in patient-based analysis. Specificity was 99% in lesion-based analysis. Pa-
tients with positive SPECT elicit higher levels of parathyroid hormone and higher weight of
resected parathyroids than SPECT-negative patients. Duration of parathyroid surgery was
on average, approximately 40 minutes shorter in SPECT-positive than in SPECT-negative
patients (89±46 vs. 129±41 minutes, p=0.006); 86% of SPECT-positive and 50% of
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SPECT-negative patients had minimal invasive surgery (p = 0.021). SPECT had lower sen-
sitivity (60%) in patients with tertiary hyperparathyroidism; however, 90% of these patients
had multiple lesions and all of these patients had bilateral lesions.
Conclusion
Dual-isotope SPECT with 99mTc-tetrofosmin and 123I sodium iodide has a high diagnostic
value in patients with primary hyperparathyroidism and allows for saving of operation time.
Higher levels of parathyroid hormone and higher glandular weight facilitated detection of
parathyroid lesion. Diagnostic accuracy of preoperative imaging was lower in patients with
tertiary hyperparathyroidism.
Introduction
In patients with hyperparathyroidism (HPT), accurate preoperative localization of the hyper-
active parathyroid lesions is essential for planning minimal invasive surgery. Parathyroid imag-
ing has been shown to be an effective tool in the preoperative localization of the dominant
source of the parathyroid hormone (PTH) excess [1, 2]. Several techniques have been intro-
duced, the most common are the dual-phase imaging using 99mTc-sestamibi and the dual-trac-
er imaging approach using 99mTc-sestamibi in combination with 99mTc-pertechnetate or 123I
sodium iodide; however, only the latter combination can be recorded simultaneously [3, 4]. In
direct comparison of both methods, the dual-tracer method elicited a 5–10% higher sensitivity
[3, 5–7]. The dual-tracer technique enables a 99mTc-tetrofosmin / 123I sodium iodide subtrac-
tion single-photon-emission-tomography (SPECT) for more precise localization of parathyroid
lesions. However, in a more recent study, dual-tracer SPECT imaging using 99mTc-sestamibi in
combination with 123I sodium iodide showed a relatively low sensitivity of 71% and a disap-
pointing specificity of 48% [8].
99mTc-tetrofosmin has similar uptake kinetics as 99mTc-sestamibi in the thyroid and para-
thyroid glands but only 99mTc-sestamibi has different washout kinetics in thyroid and parathy-
roid tissue [9]. Hence, in current guidelines, the use of 99mTc-tetrofosmin is recommended for
the dual-tracer imaging only [4]. Surprisingly, no study on dual-isotope imaging of 99mTc-
tetrofosmin in combination with 123I sodium iodide in HPT is available so far.
Therefore, we analyzed the accuracy of dual-isotope 99mTc-tetrofosmin and 123I sodium io-
dide SPECT in the detection of parathyroid lesion in HPT, and compared the imaging results
with the clinical and surgical findings
Methods
Patients
We screened all consecutive patients undergoing dual-isotope 99mTc-tetrofosmin and 123I sodi-
um iodide SPECT between 01/2005 and 12/2013 (n = 255). One-hundred ten patients had
SPECT prior to parathyroid surgery at the University Hospital Zurich and were eligible for fur-
ther analysis. From this total, we excluded 20 patients due to insufficient data (no pre- and
post-operative PTH levels documented). We additionally assessed clinical, laboratory and sur-
gical data. Diagnosis of primary (p-HPT, consistently with hypercalcemia) versus tertiary hy-
perparathyroidism (t-HPT, most commonly with a history of renal disease) was done
according to current clinical guidelines by specialists in endocrinology and nephrology.
Tetrofosmin and Sodium Iodide SPECT in Hyperparathyroidism
PLOSONE | DOI:10.1371/journal.pone.0129194 June 16, 2015 2 / 11
Demographic information, information on concomitant thyroid disease (as determined by thy-
roid sonography or elevated thyroid antibodies) and laboratory values (pre-operative serum
values of parathyroid hormone (PTH), calcium, phosphate, and creatinine) were collected.
PTH levels higher than 70 ng/l were considered as pathological [10]. We included post-opera-
tive laboratory values within an interval of up to 3 months after surgery. Surgery was per-
formed by experienced endocrine surgeons after discussion of SPECT imaging results at the
interdisciplinary thyroid board at our institution. Type of operation (minimal invasive versus
bilateral neck exploration) was chosen by discretion of the endocrine surgeon; total duration of
surgery was assessed. In 3 patients, operation duration was not recorded; 7 patients received
combined parathyroid and thyroid intervention, and operation duration was therefore not
taken into consideration. If SPECT was negative, further imaging was allowed by discretion of
the endocrine surgeon to facilitate minimal invasive surgery (including sonography, computed
tomography (CT) and magnetic resonance imaging. Histopathological work-up of surgery
specimens and assessment of weight of each specimen was done according to our clinical rou-
tine by specialized pathologists. Final histopathological diagnosis was evaluated according to
current guidelines and was the reference standard in addition to post-operative PTH values.
The study was approved by the ethical review committee of canton Zurich (name: “Kanto-
nale Ethikkommission Zürich”, number of application: KEK-ZH 2013–0556). No patient re-
fused analysis of data; ethical approval included waiving of written informed consent because
of retrospective, database driven approach and anonymization of patient records prior
to analysis.
Imaging
We scanned only patients without intravenous CT contrast or other excessive iodine intake re-
cently (< 14 days). Two hours before scanning, patients received 20 MBq (±6%) of 123I sodium
iodide orally. Ten minutes before image acquisition, each patient received 500 MBq (±6%)
99mTc-tetrofosmin intravenously. SPECT imaging was acquired either on an Infinia Hawkeye 2
or Discovery NM 670 scanner (both GE Healthcare, Switzerland). Image acquisition was iden-
tical on both scanners. Simultaneous dual-energy windows were used for separated quantifica-
tion of counts with 140 keV with total width of 15 keV (range 130–145 keV) for 99mTc and 159
keV with total width of 15 keV (range 154–169 keV) for 123I. We used a circular orbit with dual
detectors in 180° angle with 30 seconds per step and 3° per step (low-energy high-resolution
collimators, matrix 128 x 128, pixel size 4.8 mm). Image reconstruction was performed on
scanner console with scatter correction and OSEM (ordered subset expectation maximization)
reconstruction with 2 iterations. A Hanning prefilter and a Butterworth postfilter were used in
image postprocessing.
A board-certified nuclear medicine physician analyzed images blinded to results of opera-
tion. Image analysis was done with PMOD program (PMOD, Switzerland). 123I SPECT images
were normalized to 99mTc images by calculating the quotient between both images in a volume
of interest (VOI) in the center of the thyroid by taking the mean value in this VOI. Each voxel
of the 123I SPECT image was then divided by this factor. In a second step, each voxel of the nor-
malized 123I SPECT image was subtracted from the corresponding 99mTc SPECT image. Manu-
al adjustment of normalization-factor was possible by the discretion of the rater to overcome
over-subtraction [4]. A focal spot of residual activity on the subtraction image was defined as
positive finding and allocated to an anatomical location (left and right upper pole, left and
right lower pole and ectopic). An example is given in Fig 1.
Tetrofosmin and Sodium Iodide SPECT in Hyperparathyroidism
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Statistics
Statistical analyses were performed using SPSS (version 21). Data were checked for normal dis-
tribution using Kolmogorov-Smirnov test (p> 0.05 used). For average comparison of normal
distributed values, we used Student’s T-test, for non-normal distributed values Mann-Whit-
ney-test, and for nominal values Chi-square test. All group data is described by mean and
standard deviation.
Results
Demographic and clinical characteristics of patients are summarized in Table 1. We included a
total of 90 patients, 70 patients with p-HPT (mean age 56.6±12.5 years) and 20 patients with t-
HPT (mean age 47.0±13.6 years). No patient experienced side effects from dual-isotope imag-
ing. Patients with t-HPT were significantly younger and more equally distributed with regard
to gender than patients with p-HPT (p = 0.004, and p = 0.011, respectively). T-HPT patients
had higher levels of PTH (815.4±710.1 vs. 179.5±197.7 ng/l, p<0.001) and creatinine (492.1
±450.0 vs. 76.6±18.6 μmol/l, p<0.001). Approximately 40% of all patients had concomitant
thyroid disease; among these, 9 patients were on thyroid hormone replacement therapy for hy-
pothyroidism and 29 patients had thyroid nodules.
Fig 1. Example of dual-isotope 99mTc-tetrofosmin and 123I sodium iodide single-photon-emission-computed-tomography (SPECT). 123I sodium
iodide image (middle panel) was semi-manually normalized to 99mTc-tetrofosmin image (upper panel) and afterwards subtracted from it (lower panel).
Adenoma was detected at the right lower pole of the thyroid and patient received minimal invasive surgery (duration of surgery 90 minutes).
doi:10.1371/journal.pone.0129194.g001
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SPECT was performed 4.8 months on average prior to surgery. After operation, calcium
and PTH levels were available in 20 t-PTH (100%) and 69 p-HPT patients (99%), respectively.
In p-HPT, 4 patients had elevated PTH levels post-operative, 2 patients had only slight eleva-
tion (77.5 and 83.1 ng/l) with regular calcium levels and further follow up of 6 months did not
show a pronounced increase of PTH. The other 2 patients had stronger elevation (129.5 and
130.4 ng/l) but none of them elicited elevated calcium levels either. PTH levels resolved to nor-
mal in one patient during further follow-up of 6 months. In t-HPT, 5 patients elicited elevated
PTH post-operative and 4 patients were hypercalcemic; all of these patients had partial resec-
tion and were treated conservatively during further follow-up.
In patients with p-HPT, SPECT suspected one pathological parathyroid lesion in 57 of 70
patients (81% defined as SPECT positive results). Pathology confirmed a pathological lesion in
53 of the 57 SPECT-positive lesions (= 93% positive predictive value, PPV); in 4 SPECT-posi-
tive lesions, regular parathyroid tissue was found at this site. In 50 of 57 patients (= 88%),
SPECT-positive lesion was the only confirmed pathological parathyroid lesion. Patient-based
sensitivity was 80%. In 13 of all 70 patients (19%), SPECT did not show suspicious focal uptake
despite elevated PTH level at time-point of imaging. In a lesion-based approach, giving 5 possi-
ble locations for a lesion per patient (left and right upper pole, left and right lower pole and ec-
topic location: 5 locations x 70 patients = 350 possible locations), specificity was 99%.
Sensitivity was 67% with stable positive predictive value of 93% on lesion-based analysis
(Table 2).
Comparison of p-HPT patients with positive SPECT versus negative SPECT revealed signif-
icantly higher PTH levels (195.4±214.9 vs. 109.5±53.1 ng/l, p = 0.033) and higher weight of
pathologic parathyroids (1.8±2.1 vs. 0.5±0.6 g, p = 0.007) in SPECT positive patients (Table 3).
In these patients, underlying pathology was more often an adenoma than a hyperplastic para-
thyroid compared to patients with negative SPECT (p = 0.021). Total duration of parathyroid
Table 1. Demographic and clinical characteristics of patients.
all p-HPT t-HPT p
n 90 70 20
Demographics
Female 63 (70%) 54 (77%) 9 (45%) 0.011
Male 27 (30%) 16 (23%) 11 (55%)
Age [years] 54.4±13.3 56.6±12.5 47.0±13.6 0.004
Concomitant thyroid disease 38 (42%) 29 (41%) 9 (45%) 0.13
Pre-operative (percent of patients with laboratory value)
PTH [ng/l] 320.8±456.8 (100%) 179.5±197.7 (100%) 815.4±740.1 (100%) <0.001
Calcium [mmol/l] 2.8±0.3 (100%) 2.8±0.3 (99%) 2.5±0.3 (100%) <0.001
Phosphate [mmol/l] 0.9±0.4 (93%) 0.8±0.3 (93%) 1.3±0.7 (95%) <0.001
Creatinine μmol/l] 171.0±274.1 (98%) 76.6±18.6 (97%) 492.1±450.0 (100%) <0.001
Post-operative (percent of patients with laboratory value)
PTH [ng/l] 45.3±71.3 (100%) 39.5±23.8 (100%) 66.6±145.6 (100%) 0.168
with PTH  70ng/l 90% 94% 75% 0.023
Calcium [mmol/l] 2.3±0.3 (99%) 2.4±0.1 (99%) 2.3±0.7 (100%) 0.100
with calcium  2.54 mmol/l 92% 96% 80% 0.041
Phosphate [mmol/l] 1.0±0.2 (74%) 1.0±0.2 (71%) 1.0±0.3 (85%) 0.871
PTH: parathyroid hormone, p-HPT: primary hyperparathyroidism, t-HPT: tertiary hyperparathyroidism
Normal range of values: PTH  70 ng/l, Calcium 2.09–2.54 mmol/l, Phosphate 0.87–1.45 mmol/l
doi:10.1371/journal.pone.0129194.t001
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surgery was 40 minutes shorter on average in SPECT-positive than in SPECT-negative patients
(89±46 vs. 129±4 minutes, p = 0.006). Eighty-six percent of these patients received minimal in-
vasive parathyroidectomy, and only one of them had elevated PTH during follow-up. In
SPECT-negative patients minimal invasive surgery was performed in 50% (p = 0.021).
In 20 patients with t-HPT, SPECT was positive in 12 patients (60%). Ninety percent of pa-
tients with t-HPT had more than one pathologic parathyroid in histopathology and all of these
patients had bilateral lesions. Sensitivity of SPECT was 61%, specificity was 50%, and positive
predictive value was 92% in patient-based analysis. In lesion-based analysis, SPECT had sensi-
tivity of 25% for detecting all lesions, specificity was 98% and positive predictive value was 93%
(Table 4).
Discussion
Our study on 90 patients with hyperparathyroidism demonstrates high diagnostic value of
dual-isotope 99mTc-tetrofosmin and 123I sodium iodide SPECT in primary hyperparathyroid-
ism and provides evidence for substantially shorter duration of surgery in SPECT-positive
Table 2. Contingency tables of patients with primary hyperparathyroidism.
Patient based analysis Lesion based analysis
Pathology Pathology
pos Neg pos neg
SPECT pos 53 4 57 SPECT pos 53 4 57
neg 13 0 13 neg 26 267 293
66 4 70 79 271 350
Pathology was counted as positive when a pathologic parathyroid was found at site of SPECT lesion
SPECT: single photon emission tomography, pos: positive, neg: negative.
doi:10.1371/journal.pone.0129194.t002
Table 3. Differences in demographics, laboratory values, gland weight and duration of surgery in SPECT- positive and - negative p-HPT subjects
in patient based analysis.
SPECT positive SPECT negative p
n 57 13
Age [years] 55.8±12.4 59.7±13.2 0.317
Concomitant thyroid disease 37% 62% 0.625
Pre-operative (percent of patients with laboratory value)
PTH [ng/l] 195.4±214.9 (100%) 109.5±53.1 (100%) 0.033
Calcium [mmol/l] 2.8±0.3 (100%) 2.8±0.3 (92%) 0.101
Phosphate [mmol/l] 0.8±0.3 (93%) 0.8±0.1 (92%) 0.045
Post-operative (percent of patients with measurement)
Weight of pathologic parathyroid [g] 1.8±2.1 (91%) 0.5±0.6 (77%) 0.007
Histopathologic diagnosis:
Adenoma 60% 15% 0.021
Hyperplasia 33% 77%
Surgery (percent of patients with measurement)
Duration of surgery [min] 89±46 (88%) 129±41 (77%) 0.006
PTH: parathyroid hormone
Normal range of values: PTH  70 ng/l, Calcium 2.09–2.54 mmol/l, Phosphate 0.87–1.45 mmol/l
doi:10.1371/journal.pone.0129194.t003
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patients. In tertiary hyperparathyroidism, however, diagnostic performance of dual-isotope
SPECT was considerably lower in our cohort.
Up to date, multiple different scintigraphic and SPECT-based methodologies for detecting
pathological parathyroids have been described, including dual-phase, dual-isotope, planar and
CT combined imaging approaches, with wide range of sensitivity and specificity for each meth-
od [4, 6, 11–14]. Different approaches in calculation of sensitivity and specificity were used
with different references as gold standard. Especially, selection of gold standard for true nega-
tives (meaning physiological, “healthy” parathyroid glands) is challenging as the desired histo-
pathological proof of all parathyroids in each patient is not achievable. Nevertheless, taking
different standards for calculation can result in difficulties in comparison of results [8, 11].
Therefore, we calculated a patient-based analysis and a lesion-based approach including all
possible locations. Correct identification of all pathological parathyroids by surgery in each pa-
tient was ascertained by follow-up PTH and calcium testing. In p-HPT, calculated sensitivity of
the dual-isotope 99mTc-tetrofosmin and 123I sodium iodide SPECT was 80% and in the upper
range of previously published data with a very high PPV of 93% [4, 15]. Ninety-four percent of
patients had normal values of PTH after surgery, pointing to a high rate of cure and good feasi-
bility of used gold standard. Four patients had elevated levels, but 2 patients had only mild ele-
vation without any further increase in the next 6 months. These 2 patients might therefore be
stated as cured, too. The other 2 patients had stable PTH levels>100 ng/l during the next 6
months. As all patients had stable normal levels of calcium, no further surgery was indicated
and no follow-up image was performed. Discordance of elevated PTH and normal calcium lev-
els might represent pathophysiological adaptation.
Only 4 patients had a false positive scan with regular parathyroid tissue at site indicated by
SPECT. Due to the very low pre-test probability of patients without any parathyroid pathology
(as all patients had elevated PTH and clinical diagnosis of p-HPT), these 4 scans resulted in
low specificity in patient based analysis as no patient was without pathological parathyroid
gland and counted as true negative. In the lesion-based approach with more realistic pre-test
probability, specificity was excellent with 99% taking 5 possible sites and still 99% if ectopic po-
sition was excluded. This is higher than previous reports for different imaging approaches [8,
14].
In our analysis of influencing factors of parathyroid detection in p-HPT, patients with a
positive 99mTc-tetrofosmin and 123I sodium iodide SPECT scan had higher pre-operative levels
of PTH and higher weight of pathological parathyroids than patients with negative SPECT.
This relationship is reported for dual-isotope 99mTc-sestamibi and 123I sodium iodide imaging
as well as for 99mTc-sestamibi dual-phase scanning [3, 8, 16, 17]. As higher levels of PTH points
to a higher biological activity of the lesion, a stronger uptake of the mitochondrial tracers
Table 4. Contingency tables of patiens with tertiary hyperparathyroidism.
Patient based analysis Lesion based analysis
Pathology Pathology
pos neg pos neg
SPECT pos 11 1 12 SPECT pos 14 1 15
neg 7 1 8 neg 43 42 85
18 2 20 57 43 100
Pathology was counted as positive when a pathologic parathyroid was found at site of SPECT lesion
SPECT: single photon emission tomography, pos: positive, neg: negative.
doi:10.1371/journal.pone.0129194.t004
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tetrofosmin and sestamibi can be assumed from pathophysiological considerations. We ob-
served also a better detection of parathyroid adenomas than parathyroid hyperplasia. Lower
sestamibi uptake was reported for parathyroid hyperplasia compared to adenomas which
might be due to different biochemistry of these entities [17, 18]. As tetrofosmin, used in our
study, has similar uptake into parathyroid lesions as sestamibi, mentioned results obtained for
sestamibi in hyperplasia might be transferable to tetrofosmin [9]. This would be in line with
our results of significant higher percentage of hyperplastic parathyroids in SPECT negative
patients.
In our p-HPT cohort, a relatively high proportion of 41% of patients had thyroid disease
that is similar to the rate reported by Hassler and colleagues who did find a marked decrease in
sensitivity to 62% compared to 85% in patients without thyroid disease [11]. Concomitant thy-
roid nodules might elicit increased or decreased iodine uptake, thereby perturb subtraction
image. Supra-physiological thyroid hormone intake and hypothyreoidism can lead to de-
creased iodine uptake; however, we did not observe hampered uptake in critical re-analysis of
images. Although patients with SPECT-negative lesions tend to have more often concomitant
thyroid disease, differences were not statistical significant in our analysis. In a more detailed
study on concomitant thyroid diseases by Rink and colleagues, only size of the thyroid influ-
enced sensitivity and specificity but not morphological or functional alterations; this might ex-
plain differences [19]; however, we did not calculate total thyroid volume in our analysis.
Our study indicated that pre-operative dual-isotope 99mTc-tetrofosmin and 123I sodium io-
dide SPECT imaging can substantially save time of operation in patients with positive SPECT,
on average 40 minutes. Cost-calculations for operation time assume € 17–18 per minute in
Switzerland which is supposed to be in similar range in other European countries [20]. As
SPECT was positive in 81% of patients with p-HPT and duration of surgery was 40 minutes
shorter in these patients, this resulted in 2280 saved minutes and € 41’000.- in our cohort of 70
patients. Shorter operation time is achieved by minimal invasive parathyroidectomy, done in
86% of SPECT-positive patients in our cohort, which is favored by endocrine surgeons not
only due to faster intervention but lower risk of complications [4, 21]. Guiding principle for
this approach is the need of a high PPV of indicated lesion by SPECT which was 93% in our
analysis. In our study, endocrine surgeons could decide surgical approach in each patient.
Therefore, the shorter duration and implementation of minimal invasive parathyroidectomy in
86% of SPECT positive patients reflects high acceptance of pre-operative parathyroid imaging
for minimal invasive surgery planning. High rate of post-operative cure in this group affirms
this approach which was not inferior to the reported 95% cure in bilateral cervical neck explo-
ration without pre-operative imaging in p-HPT [22]. Hence, our results confirm feasibility and
cost-efficiency of pre-operative imaging with dual-isotope 99mTc-tetrofosmin and 123I sodium
iodide SPECT in patients with p-PHT as reported for other tracers [4, 23].
In patients with t-HPT, dual-isotope 99mTc-tetrofosmin and 123I sodium iodide SPECT had
lower sensitivity of 61% in patient based-analysis. In our cohort, 90% of patients had more
than one lesion and all of these patients had lesions on both sides, therefore, minimal-invasive
surgery is only feasible in the very minority of patients. Nevertheless, pre-operative knowledge
of all pathologic lesions might increase surgical accuracy. Published data on post-operative
cure in t-HPT state higher rate of recurrence similar to our analysis with a lower rate of ap-
proximately 80% compared to patients with p-HPT [4]. Higher rate of post-operative elevated
PTH might be the consequence of intentional subtotal parathyroidectomy in patients with
renal failure [24], and the subset of four patients with hypercalcemia in our analysis underwent
only partial resection of parathyroid tissue, too. In current guidelines, the value of pre-opera-
tive imaging is still considered unclear and undetermined; bilateral cervical exploration still re-
mains the standard surgical approach [3, 15]. Sensitivity for detection all lesions in patients
Tetrofosmin and Sodium Iodide SPECT in Hyperparathyroidism
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with t-HPT in our cohort was rather disappointing with only 25% which may be due to the fact
that patients with false-negative scans more often had 3 or 4 pathological lesions, with glandu-
lar hyperplasia as most common histopathological finding. Other authors reported superior di-
agnostic performance with nearly 80% sensitivity, especially for dual-isotope 99mTc-sestamibi
and 123I sodium iodide imaging [25, 26]. Noticeable in our analysis, only few images were
judged as showing multiple lesions, reflecting a possible pitfall in subtraction imaging when
over-subtraction occurs and lesions with only subtle increased uptake are deleted [4]. Newer
positron emission tomography (PET) tracers like 11C-methionine and 18F-choline have been
reported to have higher uptake in glandular hyperplasia and in SPECT-negative lesions. There-
fore, these tracers might allow better diagnostic accuracy in t-HPT; however, experience and
availability is limited [13, 27, 28].
We did not use co-registration with CT which might be one limitation of our study. Howev-
er, use of CT can improve anatomical localization but changes of diagnosis were rare in a head-
to-head comparison to SPECT imaging only [29, 30]. Another limitation of our study is the rel-
ative short duration of the laboratory follow-up of only 3 months. In a large analysis of patients
undergoing surgery for p-HPT, however, only 3 of 656 patients developed elevated PTH levels
after 6 months despite regular levels 10 days after operation [1].
In conclusion, dual-isotope SPECT with 99mTc-tetrofosmin and 123I sodium iodide has a
high diagnostic value in patients with primary hyperparathyroidism and allows for saving of
operation time and costs. Pre-operative value of dual isotope SPECT in tertiary hyperparathy-
roidism remains uncertain but newer PET tracers might overcome shortcomings in
diagnostic sensitivity.
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